Akebia Therapeutics (NASDAQ:AKBA) Announces Earnings Results

Akebia Therapeutics (NASDAQ:AKBA) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04), Zacks reports. The business had revenue of $36.90 million during the quarter, compared to analyst estimates of $46.94 million. Akebia Therapeutics had a negative return on equity of 88.88% and a negative net margin of 13.54%.

Here are the key takeaways from Akebia Therapeutics’ conference call:

• The 2,116-patient VOICE trial showed a 10% reduction in hospitalizations with Vafseo versus ESA and met its primary endpoint for superiority, with no significant mortality difference. Akebia also reported VOCAL topline results showing Vafseo was non-inferior to ESA in maintaining hemoglobin with three-times-weekly dosing.
• Vafseo patients on therapy grew about 140% year over year, but Q3 product revenue rose only 3% to $14.8 million. Akebia attributed the gap to customer inventory drawdowns tied to lower-than-expected dosing and dialysis attendance, estimating underlying Q3 end-user demand at $19–$20 million.
• As Vafseo’s separate TDAPA reimbursement ends on January 1, 2027, Akebia expects annual therapy costs to fall to roughly $1,000–$1,500, reflecting lower ESA prices, dosing, and compliance. DaVita plans a gradual rollout, while Fresenius remains interested but is expected to move more slowly.
• Q3 total revenue fell to $36.9 million from $58.8 million a year earlier, largely as Auryxia revenue dropped to $20 million from $42.5 million amid generic competition and pricing pressure. Akebia recorded a $14.4 million net loss, compared with $0.5 million of net income in Q3 2025.
• Akebia’s phase II trials of praliciguat in FSGS and ebribafusp across C3G, IgAN, and lupus nephritis are enrolling; initial ebribafusp data are expected in 2027, while no praliciguat data timing was provided. The company ended the quarter with $159.3 million in cash and said it expects to fund its current operating plan for at least two years.

Akebia Therapeutics Trading Down 5.7%

Shares of AKBA opened at $0.40 on Friday. Akebia Therapeutics has a twelve month low of $0.36 and a twelve month high of $2.07. The firm has a market capitalization of $111.20 million, a P/E ratio of -2.51 and a beta of 0.24. The company has a current ratio of 1.43, a quick ratio of 1.35 and a debt-to-equity ratio of 0.99. The firm’s 50-day moving average is $0.81 and its two-hundred day moving average is $1.13.

Analyst Ratings Changes

Several research firms recently commented on AKBA. Leerink Partners lowered shares of Akebia Therapeutics from an “outperform” rating to a “market perform” rating and set a $1.00 target price on the stock. in a report on Friday, August 7th. Wall Street Zen raised Akebia Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, November 1st. Weiss Ratings downgraded shares of Akebia Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 2nd. HC Wainwright reiterated a “buy” rating on shares of Akebia Therapeutics in a report on Thursday, August 6th. Finally, Westpark Capital began coverage on shares of Akebia Therapeutics in a report on Tuesday, September 8th. They set a “buy” rating and a $4.50 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $3.90.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for patients with kidney disease and related conditions. The company’s primary areas of interest include anemia associated with chronic kidney disease (CKD), iron deficiency, and disorders involving mineral metabolism.

Akebia’s key product is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor designed to stimulate the body’s natural production of erythropoietin and support red blood cell formation.